Publicaciones en colaboración con investigadores/as de Universitat de Barcelona (36)

2024

  1. The Effect of Polymorphisms and Other Biomarkers on Infliximab Exposure in Paediatric Inflammatory Bowel Disease: Development of a Population Pharmacokinetic Model

    Pediatric Drugs, Vol. 26, Núm. 3, pp. 331-346

2023

  1. Key Factors Associated With Pulmonary Sequelae in the Follow-Up of Critically Ill COVID-19 Patients

    Archivos de Bronconeumologia, Vol. 59, Núm. 4, pp. 205-215

2022

  1. Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID study

    Intensive Care Medicine, Vol. 48, Núm. 7, pp. 850-864

  2. One-year mortality after ICU admission due to COVID-19 infection

    Intensive Care Medicine

  3. Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 9, pp. e844-e852

2021

  1. Corticosteroid-binding-globulin (CBG)deficient mice show high pY216-GSK3β and phosphorylated-Tau levels in the hippocampus

    PLoS ONE, Vol. 16, Núm. 2 February

  2. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial

    EClinicalMedicine, Vol. 32

2020

  1. Nebulized ivermectin for COVID-19 and other respiratory diseases, a proof of concept, dose-ranging study in rats

    Scientific Reports, Vol. 10, Núm. 1

2018

  1. Advances in parkinson’s disease: 200 years later

    Frontiers in Neuroanatomy, Vol. 12

  2. Structure-activity relationship of new antimalarial 1-aryl-3-susbtituted propanol derivatives: Synthesis, preliminary toxicity profiling, parasite life cycle stage studies, target exploration, and targeted delivery

    European Journal of Medicinal Chemistry, Vol. 152, pp. 489-514

2017

  1. A biophysical study of gene nanocarriers formed by anionic/zwitterionic mixed lipids and pillar[5]arene polycationic macrocycles

    Journal of Materials Chemistry B, Vol. 5, Núm. 17, pp. 3122-3131

  2. Cytochrome P450/ABC transporter inhibition simultaneously enhances ivermectin pharmacokinetics in the mammal host and pharmacodynamics in Anopheles gambiae

    Scientific Reports, Vol. 7, Núm. 1

  3. GPR55: A therapeutic target for Parkinson's disease?

    Neuropharmacology, Vol. 125, pp. 319-332

  4. Unveiling the metabolic changes on muscle cell metabolism underlying p-phenylenediamine toxicity

    Frontiers in Molecular Biosciences, Vol. 4, Núm. MAR

2016

  1. Modeling respiratory depression induced by remifentanil and propofol during sedation and analgesia using a continuous noninvasive measurement of pCO2

    Journal of Pharmacology and Experimental Therapeutics, Vol. 356, Núm. 3, pp. 563-573

2015

  1. Critical factors to be considered when testing nanomaterials for genotoxicity with the comet assay

    Mutagenesis, Vol. 30, Núm. 1, pp. 85-88

  2. Decreased levels of guanosine 3', 5'-monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer's disease

    Neuropathology and Applied Neurobiology, Vol. 41, Núm. 4, pp. 471-482

2013

  1. CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients

    Neurobiology of Aging, Vol. 34, Núm. 3, pp. 805-808

  2. Modeling the influence of the A118G polymorphism in the OPRM1 gene and of noxious stimulation on the synergistic relation between propofol and remifentanil: Sedation and analgesia in endoscopic procedures

    Anesthesiology, Vol. 118, Núm. 6, pp. 1395-1407

2012

  1. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia

    Leukemia, Vol. 26, Núm. 7, pp. 1517-1526